

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

|                               |                |
|-------------------------------|----------------|
| <b>Application Number</b>     | 10/521,675     |
| <b>Filing Date</b>            | April 19, 2006 |
| <b>First Named Inventor</b>   | YOO, Won Il    |
| <b>Art Unit</b>               | 1646           |
| <b>Examiner Name</b>          | N/A            |
| <b>Attorney Docket Number</b> | 59520-00009    |

Sheet 1 of 1

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|--------------------|-----------------------|---|----------------|
|                    | C1                    | RODRIGUEZ-SEGAE ET AL., "High Serum IgA Concentrations in Patients with Diabetes Mellitus. Age-wise Distribution and Relation to Chronic Complications," Clinical Chemistry, 42:7 1064-1067 (1996)  |                |
|                    | C2                    | LEE ET AL., "Immunoglobulin a Nephropathy in Patients with Non-Insulin Dependent Diabetes Mellitus," Journal of Korean Medical Science, 14: 582-585 (1999)  |                |
|                    | C3                    | NICOLOFF ET AL., "An Association of Anti-Elastin IgA Antibodies with Development of Retinopathy in Diabetic Children," General Pharmacology 35: 83-87 (2000)  |                |
|                    | C4                    | KAWAMURA ET AL., "Nucleotide Sequence of the Gorilla Immunoglobulin Alpha1 Gene," Nucleic Acids Research, 17:16 6732 (1989)   |                |
|                    |                       |   |                |
|                    |                       |   |                |
|                    |                       |   |                |
|                    |                       |   |                |
|                    |                       |   |                |
|                    |                       |   |                |
|                    |                       |   |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 C.F.R. 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.